rise challeng initi outperform pt
initi coverag ascendi asnd outperform rate
price target innov parenter drug deliveri asnd develop pipelin
candid need inject once-weekli henc offer meaning
improv once-daili version compani initi commerci opportun
larg pediatr growth hormon replac market ww
us/eu regulatori submiss slate year manag
hypoparathyroid chronic form affect patient access
market optimist key upcom clinic data third achondroplasia
see asnd fast-follow forg indic
develop path expect asnd outperform high-valu therapeut asset
advanc toward market
reduc inject frequenc transcon mani inject
biolog requir frequent daili dose due short half-liv bodi
chemic linkag inert carrier molecul liber select drug
unmodifi form time asnd platform enabl once-weekli dose
extens clinic test shown transcon safe well-toler
candid patent exclus
commerci pediatr growth hormon defici next year weekli
transcon hgh demonstr superior height veloc vs daili hgh
sustain one year pediatr ghd registr program
safeti immunogen adher facilit conveni small-
needl auto-injector launch survey indic broad interest among us
specialist use transcon hgh shortli follow avail
phase hypoparathyroid readout come soon beyond lower
exposur profil rel exist daili pth product natpara sale
current subject fill-finish-rel recal see like success
transcon pth intern dose-find phase trial conduct
pen injectoran interim look posit
best-in-class achondroplasia round clinic pipelin clinic
proof concept exogen correct genet short-statur syndrom
establish daili vosoritid yet fleet half-lif like impact
efficaci clean safeti seen transcon phase continu
exposur offer potenti greater benefit phase evalu begun
dose-escal occur throughout
solid financi balanc anticip fund
compani transcon hgh launch
year price histori asnd
ascendi pharma late stage clinic
on-market
analyst certif import disclosur see disclosur
innov parenter drug deliveri asnd develop
pipelin candid need inject once-
weekli henc offer meaning improv once-
larg pediatr growth hormon replac market
world-wide us/eu regulatori submiss slate
year manag hypoparathyroid
chronic form affect patient access market
optimist key upcom clinic data third
achondroplasia see asnd fast-follow
forg indic develop path
expect asnd outperform high-valu therapeut asset
advanc toward market
ascendi take market share pghd manag
peak penetr peak net sale
ascendi modest penetr aghd peak net sale
ascendi peak penetr chronic subset pth
patient attain peak net sale
transcon-cnp reach market gener peak net
sale
six-month data transcon pth phase ole
initi pghd trial japan
initi ph ach china w/visen
submit ind/equiv first oncolog program
long-act growth hormon fail ascendi take
market share pghd best-in-class molecul
transcon-pth dose schedul allow better adher
expans pth util
transcon-cnp price higher project annual net
long-act growth hormon reach market good
enough signific commerci uptak
transcon-pth fail clinic develop
natpara return market earlier expect split market
transcon-pth
valu asnd per share use risk-adjust discount cash flow analysi valuat obtain assign
likelihood transcon hgh achiev project sale pediatr adult ghd likelihood transcon
pth achiev project sale likelihood transcon achiev project sale achondroplasia
forecast risk-unadjust revenu respect assumpt includ wacc
risk includ transcon hgh fail secur market approv transcon hgh sale under-perform project transcon
pth fail clinic develop transcon fail clinic develop unexpect industri competit aris
tabl content
applic proprietari drug deliveri technolog ascendi pharma
asnd gener best-in-class pipelin candid develop
treat endocrin disord candid meaning decreas inject
frequenc approv well-valid drug may improv efficaci and/or
safeti asnd growth hormon candid transcon hgh success
complet phase program pediatr growth hormon disord soon
enter review us eu approv potenti compet
market earli phase data transcon pth hypoparathyroid
anticip come week believ candid may abl offer
safeti advantag takeda natpara sale transcon
offer potenti better efficaci achondroplasia rel bmrn
vosoritid sale potenti per consensu posit phase
result recent report believ transcon technolog may broadli
appli inject biolog address dose frequenc deliveri
limit exemplifi compani pre-clin oncolog asset
indic announc third therapeut area interest near futur
expect asnd share outperform high-valu therapeut asset advanc
toward market
underpin outperform rate
oppenheim growth hormon survey us pediatr endocrinologist
expect use transcon hgh most-to-al elig patient
within short time becom avail
conduct guidepoint februari
clinic regulatori news flow
phase data transcon pth march-april
us eu approv decis transcon hgh
potenti earli human data oncolog asset
initi transcon hgh phase program adult ghd
initi transcon cnp phase program hypoparathyroid
initi phase achondroplasia trial
valuat deriv sum-of-the-part methodolog
present valu key pipelin product risk-adjust asnd lead product
transcon hgh long-act human growth hormon assign
probabl approv achiev sale estim
treatment growth hormon defici children adult respect
assign probabl success compani long-act
version parathyroid hormon transcon pth hypoparathyroid c-
type natriuret peptid transcon achondroplasia respect
model approxim peak global sale pediatr hgh adult
hgh hypoparathyroid achondroplasia assign
valu pre-clin oncolog asset potenti expans indic use
transcon technolog asnd report financi euro assum
convers rate usd/eur
estim termin valu mean gordon growth model
assum termin growth rate wacc price target imput
share outstand reflect expect dilut next year
potenti upsid catalyst price target includ failur
long-act growth hormon reach market greater penetr hgh
market forecast price transcon product premium current
therapi pth asset reach market faster project
risk achiev price target includ clinic develop
disappoint failur secur market approv lower sale vs
estim heavier commerci expens vs estim need achiev
sale expect unexpect safeti issu unforeseen competit
earlier and/or greater eros gener copi
productev timingtranscon hghiniti global phase adult pthtop-lin phase data hypoparathyroidismmar-apr hghbla file pediatr pthsix-month phase extens hghmaa file pediatr hghiniti phase pediatr ghd pthiniti global phase cnpiniti phase achondroplasia first hghpotenti fda approv pediatr asnd outperform
ascendi pharma asnd develop stabil form clinic valid molecul
use transcon technolog allow sustain predict releas
parent drug enabl greatli improv pk/pd profil optim dose
endocrinolog asset ascendi later stage clinic develop
endocrinolog pipelin consist three endocrin assetspediatr adult
human growth hormon parathyroid hormon c-natriuret peptid
compani also early-stag oncolog asset includ transcon
transcon tlr agonist transcon vegf-tki also expand
util transcon technolog anoth therapeut area yet
ascendi commerci global endocrinolog asset
develop strategi commerci greater china joint ventur
creat investor syndic
ascendi transient conjug technolog allow bind parent drug
inact carrier varieti linker moieti linker
cleavag rate releas parent drug determin consist rate
ascendi develop array linker molecul allow differ
releas rate differ half-liv depend ph temperatur
environ transcon technolog allow once-daili once-weekli even
twice-yearli dose variou parent drug
compani also util two type carrier deploy prodrug
solubl insolubl ofit endocrinolog asset use solubl carrier
compani plan use insolubl carrier intra-tumor oncolog inject
growth hormon somatotropin vital import hormon well-
known stimul growth height mani may realiz
indirectli involv array vital process includ height bodi composit
mental health cardiovascular health bone health stimul
secret insulin-lik growth
exhibit human growth hormone/act product
gh act bind specif receptor predomin locat liver
trigger phosphoryl cascad result secret
mediat major peripher action gh growth-promot
effect almost everi cell bodi stimul dna synthesi cell cycl
progress anabol activ cellular repair strong agonist trigger
signal pathway
side effect growth hormon vari pediatr adult adult gh
administr often involv fluid retent swell joint pain tingl
nerv hyperinsulemia may lead cardiovascular complic
though complic gener rare spectrum side effect seen
adult also seen children children also headach
increas intraocular pressur progress curvatur spine
scoliosi repeat inject gh inject site result
lipoatrophi adult children develop neutral antibodi gh
treatment negat benefit
studi design result
ascendi develop three major trial evalu transcon hgh height
flight fed extens trial enlighten allow biolog licens
applic bla submiss
height enrol treatment-nav subject primari outcom annual
height veloc vertic growth child specifi unit time
week multicent random open-label parallel assign trial
transcon hgh assign one group genotropin anoth height manag
estim treatment improv genotropin
p-valu
exhibit poor respondership daili growth hormon treatment
height show import improv genotropin incid
poor respond defin patient less averag
height veloc ahv transcon hgh patient present
poor respond trial patient genotropin arm present
poor respond independ studi suggest rate poor
respond genotropin arm could low comparison natur histori
flight enrol treatment-experienc patient intent show similar
height veloc compar treatment-nav patient ahv week mean
cm/year across age gender appropri higher ahv kid
year age expect treatment-nav patient transcon hgh
show advers event profil compar daili hgh popul
patient height flight roll extens trial enlighten
show long-term effect transcon hgh enrol patient
importantli show improv ahv patient switch
genotropin transcon hgh unexpect side effect issu aros
expect see bla pediatr ghd submit market
author applic submit would expect see ascendi
market
childhood-onset growth hormon defici identifi approxim
newborn children also subset children acquir growth
hormon defici injuri infect growth hormon would
administ year old year old approxim around time
growth plate fuse patient complet defici growth hormon
product may remain therapi lifetim combat neg
effect diminish gh product
growth hormon also use number use beyond ghd turner syndrom
idiopath short statur prader-willi syndrom small gestat age
growth hormon market well-defin approxim annual sale
on-label pediatr indic approxim half on-label pediatr
indic growth hormon defici children half rare
diseas subtyp mention previous ascendi expans
trial pediatr growth hormon prodrug encompass neglect
market fairli evenli split five major brandsnorditropin omnitrop
humatrop nutropin genotropin norditropin market leader may
primarili due ownership premier administr devic field
exhibit consensu poll us physician prefer daili hgh
data reflect respons survey us pediatr endocrinologist conduct guidepoint februari
data shown humatrop prefer
current once-daili hgh peptid avail market howev
lengthi race get long-act growth hormon prepar
market earli genentech brought nutropin depot market long-
act growth hormon howev discontinu lack commerci
success due needl size larg gaug needl
creat unseemli bolu lump medic upon administr last
day ascendi auto-injector gaug mm needl low volum
inject allevi problem dose needl size minim amount
fluid lump eas administr
despit failur industri produc long-act growth hormon mani
molecul still develop once-weekli inject treat growth hormon
exhibit long-act growth hormon develop
long-act growth hormon prepar treatment children lal hoffman
number techniqu attempt creat new formul
long-act growth hormonedepot pegyl albumin bind gh fusion
somatrogon produc partner rhgh fuse
three copi hcg beta subunit post phase non-inferior data fail
match ascendi superior data actual under-perform daili
compar arm safeti concern regard size molecul
potenti trigger neutral antibodi view ascendi approach
far cleaner profil significantli better data threat
somatrogon see commerci would market machin
encroach expans opportun ahead ascendi
somapacitan develop novo nordisk rhgh single-point mutat
attach termin fatti acid recent posit phase result
attract somatrogon result howev still year away
commerci still look inferior ascendi molecul somapacitan
potenti competitor upon commerci ascendi
head start superior technolog believ ascendi manag take
largest share growth hormon market virtu pro-drug formul
coupl expect best-in-class injector devic
companyproductdesignstatusgenentechnutropin depotencapsul polylactide-coglycolid microspheresremov market nordisksomapacitanhgh singl point mutat attach termin fatti acidin phase transient bound mpegposit phase data superior daili hghopko/pfizersomatrogonhgh fuse copi carboxy-termin hcg beta subunitphas data show non-inferior daili hghgenexinehytropinhgh fuse igd phase testingversartissomavaratanhgh fuse hydrophil string amino acidsdiscontinu due inferior daili hgh ascendi pharma
perform survey pediatr endocrinologist get sens
physician view transcon-hgh commerci impact also want get
sens impact auto-injector integr data platform might
drive physician adopt develop market
physician demonstr expect util transcon-
hgh daili usag note extrem excit
prospect use transcon-hgh estim would use immedi
get market approxim patient anoth would
expect rapid adopt patient remain may
slightli slower adopt still much interest transcon-hgh
market
highhighmoderatelowveri lowphysician prefer prescrib transcon-hgh daili probabl commerci long-act growth hormon asnd outperform
physician poll awar major long-
act growth hormon develop strongli support transcon-hgh
somatrogon somapacitan survey physician
opinion thought highli transcon-hgh somatrogon
want get gaug impact lesser-known innov might drive
physician patient adopt within commerci atmospher ask
physician much impact premium auto-injector would
prefer prescrib growth hormon survey respond
state would least modest impact decis administ
integr data platform similarli impact state least modest
impact well fewer think substanti impact
impact prefer long-act growth data platform impact long-act growth hormon choic ascendi pharma
mention growth hormon involv number process beyond
height popul adult defici growth hormon
product replac therapi somatotropin would highli
exhibit caus hypopituitar
diagnosi adult gh defici done varieti gh diagnost test
evalu plasma level relat age cohort importantli adult
patient actual less compliant daili administr hgh children
daili subcutan inject appear major deterr util
ascendi once-weekli dose patient much amen
studi design enrol timelin
ascendi initi phase studi adult growth hormon defici
compani primarili evalu non-growth measur growth
hormon focus improv metabol marker function yet
see ascendi design phase studi aghd phase ascendi
evalu plasma level cours treatment incid anti-hgh
antibodi format well clinic safeti marker includ mean total
cholesterol mean hdl cholesterol mean triglycerid mean glucos
mean percentag evalu dose
concert omnitrop
long-act growth hormon work phase studi well opko
design phase primari outcom measur chang trunk fat
mass novo nordisk similar endpoint evalu truncal fat percentag lean
bodi mass incid advers event would expect similar endpoint
ascendi trial potenti secondari evalu bone mass serum
market size adult human growth hormon well defin major
popul adult treat adult growth hormon defici two
group children growth hormon defici adulthood approxim
pediatr popul adult sort trauma
call key opinion leader growth hormon field believ
differ opinion adult patient treat growth
hormon among physician situat lead reduct actual
treat adult popul approxim half coupl poor
adher patient popul market adult growth hormon
significantli less attract pediatr market
estim preval adult growth hormon defici
studi suggest preval adult growth hormon defici could
high childhood growth hormon defici patient roll
adulthood includ model peak penetr us
result patient treat eu indic treatment
anoth assum carry-ov pediatr popul
age adult growth hormon market significantli smaller pediatr
market model peak sale approxim
adult growth hormon market current expect overal
growth hormon market impli current total sale
mention earlier market grow approxim compound-annual-growth-rate
total adult market expans would expect
strong campaign drive better awar broad
symptom gh defici beyond fat mass/lean bodi mass believ potenti
signific penetr adult segment quit feasibl
ascendi phase parathyroid hormon asset develop
true replac therapi patient suffer hypoparathyroid
compani design linker allow once-daili dose night attempt
emul diurnal rhythm parathyroid hormon linker attach
parathyroid hormon critic hormon secret parathyroid gland
involv mainten normal serum calcium level action
bone kidney parathyroid gland calcium-sens receptor
monitor serum calcium level trigger releas pth serum calcium level
low natur parathyroid hormon half-lif minut pth
releas bodi releas tonic capac within rhythm wherea
remain use tightli regul calcium level pulsatil secret
pth act indirectli osteoclast within bone releas calcium blood
stream role kidney quit differ inhibit reabsorpt
phosphat allow remov reduct phosphat blood
plasma also convert inact form vitamin activ vitamin within
kidney increas absorpt calcium within intestin
patient chronic hypoparathyroid acut chronic
manifest diseas acut manifest due acut
hypocalcemia typic neuromuscular involv rang
paresthesia cramp involuntari sever spasm hand feet
gener seizur cardiovascular event occur involv prolong
qt interv hypotens heart failur arrhythmia chronic hypocalcemia
includ worsen acut manifest may also lead presenc basal
ganglia calcif cataract dental abnorm basal ganglia
calcif lead parkinson movement disord possibl
dementia renal diseas also occur elev likelihood nephrocalcinosi
nephrosclerosi kidney stone renal insuffici patient
patient typic acquir hypoparathyroid one four rout
parathyroid gland injuri surgic remov irradi autoimmun destruct
impair develop rare diseas specif storag disabl cancer
diagnos via persist hypocalcemia low normal pth level
alongsid hyperphosphatemia obviou event surgic
remov parathyroid gland
issu administ pth
parathyroid hormon mimic market natpara
approv treatment hypoparathyroid howev pull
market septemb due manufactur defect rubber septum
parathyroid molecul includ teriparatid tymlo
indic osteoporosi
natpara expect return market eventu howev view ascendi
daili inject far superior natpara half-lif approxim three
hour dosag mcg natpara carri rem protocol
risk osteosarcoma seen rat dose blood level
measur human maximum approv dose natpara may delay
return ascendi may actual market time natpara return
belief ascendi may abl avoid black box warn natpara
carri ascendi recent announc present fda
ema agre grant studi waiver carcinogen studi show
transcon-pth carri osteosarcoma risk natpara
mechanist flatter pk/pd profil ascendi transcon-pth
high drug level peak natpara osteosarcoma risk
theoriz caus larg puls pth act osteoblast ascendi
abl avoid black box warn also abl supplant standard care
signific upsid estim
warn potenti risk osteosarcoma male femal rat parathyroid hormon caus increas incid ofosteosarcoma malign bone tumor occurr osteosarcoma dependenton parathyroid hormon dose treatment durat effect observ atparathyroid hormon exposur level rang time exposur level inhuman receiv mcg dose natpara data could exclud risk tohuman potenti risk osteosarcoma use natpara patient bewell-control calcium activ form vitamin alon potentialbenefit consid outweigh potenti risk avoid use natpara patient increas baselin risk osteosarcomasuch patient paget diseas bone unexplain elev alkalinephosphatas pediatr young adult patient open epiphys patient withhereditari disord predispos osteosarcoma patient prior histori ofextern beam implant radiat therapi involv skeleton risk osteosarcoma natpara avail restrictedprogram risk evalu mitig strategi rem call natpararem program ascendi pharma
mention parathyroid hormon natur releas respons
parathyroid gland calcium receptor sens low serum calcium level
therefor hard creat replac therapi howev pth follow
natur diurnal rhythm pth peak night find trough
morn hour climb steadili throughout afternoon even
ascendi attempt mirror natur rhythm daili inject cycl
approxim individu us experi
hypoparathyroid approxim patient hypoparathyroid
transient cours diseas last less six month remain
patient equat chronic patient much need
replac parathyroid hormon therapi assum similar preval
hypoparathyroid eu estim chronic need parathyroid
hormon eu case assum valu rest
world row may signific patient popul due poor surgic
procedur damag parathyroid gland
ascendi recent expand enrol phase trial natpara remov
market order accommod patient need set back
ascendi data readout expect april
result slate present late march endo
confer cancel connect current coronaviru situat
believ result nonetheless dissemin around time
model ascendi penetr approxim us chronic pth
popul total patient treatment forecast
slightli lower penetr eu divers countri model
peak penetr equat patient treatment
repres annual revenu project annual wac price
model zero penetr transient popul
ascendi found superior treatment current standard care may
even modestli penetr transient market market three time larger
chronic market albeit patient short durat therapi
natriuret peptid critic ill
molecul innat ring structur amino acid smaller tail
anp bnp peptid shortest half-lif three
research believ tail length play role vosoritid transcon-cnp
develop around concept elong peptid tail cnp natur
half-lif quit shortaround minut comparison vosoritid half-lif
around minut transcon-cnp effect half-lif hour
c-natriuret peptid function fulli understood produc
endothelium heart appear play role vascular cardiac
function also certainli play role signal bone growth highli
conserv three identifi natriuret peptid indic import
biolog system bolu dose supraphysiolog level
shown cardiotox effect appear
cardioprotect effect physiolog level cardiotox effect
seen ascendi method administr give comfort
regard competit posit
achondroplasia disord affect bone growth especi long bone
caus mutat fibroblast growth factor receptor gene mutat
stabil activ state overact inhibit chondrocyt
prolifer lead improp bone growth present achondroplasia
play role inhibit overact see exhibit
natur function bone growth return someth approxim normal
exhibit function achondroplasia
advanc treatment achondroplasia osteoarthr et al
achrondroplasia detect prior birth prenat ultrasound complic
achondroplasia begin earli infanc increas likelihood
compress spinal cord therefor import administr
treatment begin earli possibl
c-type natriuret peptid analogu therapi children achondroplasia savararayan et al
view biomarin therapi adequ first-to-market see
treatment landscap ripe signific improv vosoritid unfortun
data children age exclud import segment
would benefit treatment children
age five biomarin studi expand treatment popul
complet around time expect ascendi may file
addit biomarin competit presenc purchas therachon mid-
therachon complet phase trial treatment achondroplasia
molecul design act synthet fibroblast growth factor receptor
order bind fibroblast growth factor diminish activ capac
see true threat ascendi potenti domin posit
found deleteri effect unforeseen
daiichi-sankyo also develop fusion molecul preclin
japan-bas drugmak fuse fragment ghrelin extend half-
life view threat ascendi molecul
incid achondroplasia fulli understood estim
live birth equat annual incid us
eu complic occur earli infanc
administr could begin immedi birth ascendi data
applic young age
assum treatment achondroplasia last normal growth plate
fusion estim year treatment per patient result effect
preval us eu rest world
similar incid achondroplasia repres upsid estim
estim durat treatment may lower treatment start later
infanc evid benefici beyond fix growth
plate may role adulthood also repres upsid
studi design timelin
biomarin trial single-arm studi evalu variou dosag across
achondroplasia patient ascendi phase trial better develop biomarin
double-blind placebo control trial enrol children arm
escal dosag visen initi phase trial achondroplasia
china estim phase trial data
visen data come shortli thereaft ascendi orphan drug
design achondroplasia two double-blind placebo-control
trial enough data abl submit nda fda
happen transcon could market
ascendi goal util transcon technolog three indic
three therapeut area describ vision second
therapeut categori behind endocrinolog select oncolog
continu await news third therapeut area interest
cytokin produc primarili cell also lesser extent
cell dendrit cell natur killer cell main function promot
develop memori regulatori cell bind receptor
cell stimul differenti cell receptor
three-chain complex alpha beta gamma chain regulatori cell
howev memori cell nk cell receptor dimer
made beta gamma chain
shown extens potenti abil produc complet respons
even stage iv solid tumor howev dose face number hurdl due
lack select rel sever side effect profil must util
small number expert immunotherapi center monitor dose result
cytokin cascad supraphysiolog level lead capillari leak syndrom
end-organ dysfunct patient prolong low blood pressur
concomit high heart rate cardiovascular renal effect
infect also frequent advers event dose high-dos
exhibit demonstr receptor select
daili dose done via iv subcutan inject typic dose
daili seri round follow repriev number day ascendi
strategi inject long-act intra-tumor also design
select agonist preferenti bind receptor avoid
includ alpha chain promot greater differenti infect
may significantli lessen administr select agonist
system organ toxic effect capillari leak syndrom lessen
local administr sustain low-dos
ascendi develop transcon hydrogel load resiquimod toll-lik
receptor tlr agonist intra-tumor inject case
compani oncolog product tlr agonist preclin current
data mice
use ligand enhanc cancer immunotherapi smit et al
tlr famili pattern-recognit receptor import recognit
antigen immun cell tlr highli conserv among speci
current tlr identifi express mammal tlr close
relat locat within endosom cell tlr act recogn foreign
antigen trigger cell produc number inflammatori cytokinesil-
ifn- tnf- resiquimod tlr agonist origin develop
pharmaceut potent imiquimod
administ system result undesir system effect due
upregul inflammatori cytokin upregul manifest
fatigu decreas lymphocyt vomit fever potenti hepat renal
toxic involv well transcon product side effect profil
essenti nullifi agonist link transcon shell
vascular endotheli growth factor inhibitor util cancer therapi
attempt inhibit tumor angiogenesi build new vascular tissu
tumor limit metabol tumor slow abil grow
sustain side effect profil drug sever renal
dysfunct inhibit normal vascular develop hypertens subsequ
exhibit vegf-tki mechan action
vascular toxic vegf inhibitor therapi toutz et al
tumor angiogenesi target field oncolog time
potenti treatment neg consequ administ
system interf necessari angiogenesi ascendi believ may
inhibit tumor growth link axitinib carrier molecul inject intra-
tumor sustain local dose reduc side effect profil minim
present find mechanist sound look forward earli
human data combin trial may follow
ascendi two partnership outlicens technolog compani
issu licens transcon genentech sanofi sanofi licens
transcon technolog treatment diabet howev sanofi state
halt research diabet may result return asset
ascendi believ could boon futur indic ascendi
may pursu agreement sanofi term length patent
expir ascendi may abl negoti return asset
earlier genentech continu use licens intern develop
anti-vegf could dose infrequ bi-annu genentech
target age-rel macular degener ophthalmolog candid
ascendi also form joint ventur investor
group capit order penetr larg opportun china ascendi
own stock compani
despit transcon prodrug incorpor alreadi approv parent drug
product consid new molecular entiti mean elig
new composition-of-matt patent ascendi hold extens patent life
transcon hgh famili six patient cover one additon patent
cover usag autoinjector
first patent composition-of-matt patent regard stoichiometri
transcon hgh carrier molecul expir octob
second patent composition-of-matt regard transcon linker
expir march
third patent composition-of-matt direct broad class lead
candid structur expect expir april
fourth composition-of-matt patent regard specif dri pharmaceut
composit compris transcon hgh expir decemb
fifth composition-of-matt patent direct anoth broad class lead
candid structur expir novemb
sixth patent relat particular dosag regimen long-act growth
hormon formul also expir novemb
auto-injector patent expect allow exclus
transcon pth famili six patent cover well
first patent patent famili composition-of-matt direct
transcon linker use transcon pth note
special linker differ endocrinolog asset patent
expect expir januari
second patent composition-of-matt direct broad class pth
candid structur expir februari
third fourth patent refer method-of-treat patent particular
dosag regimen consist intern patent applic
patent expir septemb
fifth patent group patent refer famili composition-of-
profil patent also expir septemb
sixth patent relat start dose treatment revers pth
conjug patent includ ep prioriti applic patent famili
expect expir may
patent portfolio relat transcon includ ten patent famili
first patent famili composition-of-matt relat stoichiometri
carrier molecul set expir octob
second patent famili composition-of-matt direct linker
expir janari
third patent famili omposition-of-matt direct broad class
candid structur expir januari
fourth ninth patent famili patent cover composit
matter variou compound patent patent famili
expect expir januari
tenth patent cover combin therapi transcon patent
famili consist intern patent applic expect expir
septemb
mm except per share product pediatrictranscon hgh- adult transcon hgh- transcon pth- transcon cnp- net total product revenue- net collabor total cogs- total oper oper financ financ pre-tax incom tax benefit net incom sale dilut gaap dilut share flow use oper flow use flow use invest flow use financ cash equival end cash includ cash cash non-curr plant current tax cash equiti reserves- retain earn accumul deficit- total liabilities- financ leas liabilities- total current liabilities- contract trade payabl income- incom tax ascendi pharma
jan mikkelsen ceo ascendi pharma sinc co-found
compani prior ascendi spent time ceo role veloxi
pharmaceut time c-suit presid protein
pharmaceut divis maxygen also spent time vice presid protein
discoveri novo nordisk hold cand scient biochemistri odens
scott smith cfo ascendi pharma prior time ascendi head
healthcar invest bank wedbush secur year
director invest bank merril lynch prior year hold
ba economics-account physic claremont mckenna colleg also
stanford gener manag
michael wolff jensen chief legal offic chairman board
mr jensen chairman numer compani current sit
chairman ascendi xspray pharma ab eurocin vaccin cfo
life-cycle pharma genmab prior
hold lm law aarhu univers univers copenhagen
tom larson join ascendi april chief commerci offic mt
pharma america built design hire us commerci
organ also spent three year vice-president market sale commerci
oper marathon pharmaceut built commerci
infrastructur also held number sale gener manag role
boehring ingelheim abbott hold bs biochemistri northern
peter rasmussen vice-president financ princip account offic
peter rasmussen ascendi pharma sinc march vice-president
financ held varieti financ role includ time financi
consult cfo advandx head financ life-cycle pharma account
manag genmab
board director
seven individu sit ascendi board director includ four
jame heali md phd lisa bright presid intercept
pharmaceut birgitt volck hold posit presid
albert cha manag partner capit jame heali gener partner
sofinnova ventur lar holtug director held numer chairman
posit varieti compani ceo mikkelsen sit board chief
legal offic wolff jensen chairman
stock price compani mention report
